39 results
424B5
VKTX
Viking Therapeutics Inc
1 Mar 24
Prospectus supplement for primary offering
4:13pm
hedging or other transactions designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition of any shares … banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain
8-K
EX-1.1
VKTX
Viking Therapeutics Inc
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
that the foregoing precludes the undersigned from engaging in any hedging or other transactions designed or intended, or which could reasonably be expected to lead
424B5
VKTX
Viking Therapeutics Inc
27 Feb 24
Prospectus supplement for primary offering
5:21pm
or such other securities, in cash or otherwise. The foregoing precludes the lock-up party from engaging in any hedging or other transactions designed or intended … management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective
PRE 14A
10tn0
17 Apr 23
Preliminary proxy
5:04pm
8-K
EX-1.1
mnehq4ctxbfmd3 5xu
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
424B5
zcag75a
31 Mar 23
Prospectus supplement for primary offering
5:24pm
424B5
wmzxiibawbn8bdp7 ts
29 Mar 23
Prospectus supplement for primary offering
4:01pm
424B5
os160yjth3u9yg vf
21 Sep 18
Prospectus supplement for primary offering
4:16pm